Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study

Author:

Qi Huang,Xuefeng Sun,Hongli Lin,Zhimin Zhang,Lirong Hao,Li Yao,Jijun Li,Delong Zhao,Yong Wang,Hanyu Zhu,Xiangmei Chen

Abstract

Background Anticoagulation treatments are an important aspect of hemodialysis; however, few reports have addressed these treatments. This investigation intends to increase the understanding of the current status and improvements of hemodialysis-related anticoagulation treatments in China. Methods In this study, an epidemiological investigation was conducted that examined 842 patients in 2007 and 1 175 patients in 2012 who underwent hemodialysis anticoagulation treatments in seven blood purification centers in northern Chinese cities. Results Heparin was the most commonly used anticoagulant, although the percentage of use of low-molecular-weight heparin (LMWH) increased from 26.5% in 2007 to 42.1% in 2012. In 2007, there were no significant differences in anticoagulant selection among either patients with various primary diseases or patients with hemorrhage, thrombosis, thrombocytopenia, or a low hemoglobin level. However, compared with patients with other diseases, significantly lower doses of LMWH were administered to patients with hypertension (55.5 U/kg vs. 67.3 U/kg, P <0.05) or diabetes (58.5 U/kg vs. 67.3 U/kg, P <0.05), and patients with hemorrhage received lower doses of heparin than the other patients (61.6 U/kg vs. 71.8 U/kg, P <0.01). In 2012, patients with diabetic nephropathy (51.5% vs. 36.5%, P <0.01), hemorrhage (43.4% vs. 31.7%, P <0.01), or a hemoglobin level below 90 g/L (57.2% vs. 37.1%, P <0.01) experienced significantly higher doses of LMWH administration; patients with hemorrhage received significantly reduced LMWH dosages (50.4 U/kg vs. 57.8 U/kg, P <0.05), and patients with thrombosis received significantly higher doses of heparin (73.8 U/kg vs. 62.1 U/kg, P <0.01) or LMWH (57.8 U/kg vs. 52.6 U/kg, P <0.05). Antiplatelet drugs were administered to 20.4% of the examined patients in 2007 and 20.7% in 2012. In 2012, patients with hypertension (25.9% vs. 18.5%, P <0.01) and thrombosis (36.6% vs. 16.1%, P <0.01) had a higher rate of using antiplatelet drugs than patients with other primary diseases and complications. Patients receiving antiplatelet drugs also received higher doses of heparin than patients without using antiplatelet drugs (74.4 U/kg vs. 65.9 U/kg, P <0.01). However, the use of the drugs was not correlated with thrombocytopenia. The rate at which coagulation indices were determined increased from 45.7% in 2007 to 64% in 2012. Conclusion These findings suggested that hemodialysis-related anticoagulation treatments in China have gradually become more standardized and individualized.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference16 articles.

1. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system.;Nephrol Dial Transplant,2002

2. Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Dialysis adequacy (HD) guidelines.;Kerr;Nephrology (Carlton),2005

3. Epidemiology of anticoagulation for hemodialysis patients: survey of 842 cases in seven hemodialysis centers (in Chinese).;Sun;Natl Med J of Chin,2009

4. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.;Shen;Am J Kidney Dis,2012

5. The heparins: all a nephrologist should know.;Hetzel;Nephrol Dial Transplant,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3